AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.6500
+0.0600 (+1.67%)
As of 12:01PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.5900
Open3.6100
Bid3.67 x 800
Ask3.68 x 4000
Day's Range3.4900 - 3.7800
52 Week Range3.1400 - 33.2700
Volume1,275,259
Avg. Volume3,656,501
Market Cap458.046M
Beta (3Y Monthly)3.61
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est8.00
Trade prices are not sourced from all markets
  • Markit4 hours ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    # Akorn Inc ### NASDAQ/NGS:AKRX View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for AKRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $594 million over the last one-month into ETFs that hold AKRX are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
    Zacks12 days ago

    Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility

    Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.

  • PR Newswire13 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akorn, Inc. - AKRX

    NEW YORK, Jan. 9, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Akorn, Inc. ("Akorn" or the "Company") (NASDAQ:  AKRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Akorn and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On January 9, 2019, Akorn disclosed that it received a warning letter from the U.S. Food and Drug Administration, after the company's Decatur, Illinois manufacturing facility was inspected by the regulatory authority in April and May 2018.

  • Moody's13 days ago

    Akorn, Inc. -- Moody's says receipt of FDA Warning Letter on Akorn's Decatur facility is credit negative

    Moody's Investors Service commented that Akorn, Inc.'s ("Akorn") receipt of a warning letter from the US Food & Drug Administration ("FDA") related to its Decatur manufacturing facility is credit negative. The warning letter is credit negative as Akorn will be unable to have drugs approved out of that facility until the compliance issues are addressed.

  • Reuters13 days ago

    Akorn gets FDA warning letter for Illinois plant, shares drop

    Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year. The warning letter, dated Friday, lists violations related to the agency's current good manufacturing practice regulations, which include poor aseptic behavior, as well as those related to environmental and personnel monitoring. The FDA said the company's response to its Form 483, which lists observations from the inspection in April and May, was inadequate.

  • Benzinga13 days ago

    Akorn Slides After Reporting FDA Warning Letter On Illinois Facility

    Akorn said Wednesday ahead of the market open that the FDA sent a Jan. 4 warning letter tied to inspections of its Decatur, Illinois manufacturing facility that were conducted in April and May 2018. The FDA took exception to the company's failure to follow written procedures designed to prevent microbiological contamination of drug products, as well as a lack of control systems to prevent contamination and a written testing program to assess stability characteristics of drugs.

  • Reuters13 days ago

    Akorn gets warning letter from the FDA

    Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration, after the company's Decatur, Illinois manufacturing facility was inspected by the regulatory authority ...

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    # Akorn Inc ### NASDAQ/NGS:AKRX View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for AKRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding AKRX is favorable, with net inflows of $11.05 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • MarketWatch13 days ago

    Akorn receives 'warning letter' from FDA related to a manufacturing facility

    Akorn Inc. said Wednesday that it received a warning letter from the Food and Drug Administration, related to an inspection of the generic drug maker's Decatur, Illinois manufacturing facility. The stock was halted for news, and was inactive prior to the halt. The FDA had investigated the facility in April and May 2018. The company said it will respond to the FDA letter, dated Jan. 4, within 15 working days. "Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter," Akorn said in a statement. The stock has tumbled 39% over the past three months, while the S&P 500 has lost 10.6%.

  • GlobeNewswire13 days ago

    Akorn Receives FDA Warning Letter

    Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter.  The Company will respond to the FDA letter within the required 15 working days. The Company has full confidence in the quality of the products manufactured at the Decatur facility and expects to continue production at the plant.

  • GlobeNewswire14 days ago

    Akorn Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akorn, Inc. (AKRX), today announced that Akorn granted an inducement equity award in accordance with Nasdaq Listing Rule 5635(c)(4) pursuant to an employment arrangement with Akorn’s newly appointed President and Chief Executive Officer Douglas S. Boothe on January 8, 2019.

  • Business Wirelast month

    Robbins Arroyo LLP: Shareholder Lawsuit Filed Against Officers and Directors of Akorn, Inc. (AKRX)

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that a shareholder of Akorn, Inc. (AKRX) has filed a lawsuit against the company's officers and directors for breaches of fiduciary duty from 2014 through the present. Akorn is a specialty generic pharmaceutical company. According to the complaint, on April 24, 2017, Fresenius SE Co. KGaA ("Fresenius") agreed to acquire Akorn in a deal valued at $4.3 billion.

  • Archer Capital Management Return, AUM, and Holdings
    Insider Monkeylast month

    Archer Capital Management Return, AUM, and Holdings

    Archer Capital Management is a hedge fund advisory firm based in New York City and Beverly Hills, California. It was founded in January 2006 by Eric Edidin and Joshua Lobel. Eric Edidin received a BA  with highest distinction Degree from the University of Michigan and an MBA from Harward Business School. His professional experience includes […]

  • Benzingalast month

    The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 20) • XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech ...

  • Moody'slast month

    Akorn, Inc. -- Moody's downgrades Akorn's ratings to Caa1; outlook revised to negative

    Moody's Investors Service ("Moody's") downgraded the ratings of Akorn, Inc. ("Akorn") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD and the senior secured term loan rating to Caa1 from B3. Moody's also downgraded the Speculative Grade Liquidity Rating to SGL-3 from SGL-2.

  • Business Wirelast month

    Robbins Arroyo LLP: Shareholder Lawsuit Filed Against Officers and Directors of Akorn, Inc. (AKRX)

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that a shareholder of Akorn, Inc. (AKRX) has filed a shareholder lawsuit against the company's officers and directors for breaches of fiduciary duty from 2014 through the present. Akorn is a specialty generic pharmaceutical company. According to the complaint, on April 24, 2017, Fresenius SE Co. KGaA ("Fresenius") agreed to acquire Akorn in a deal valued at $4.3 billion.

  • After court case loss, drug maker Akorn's CEO will step down
    American City Business Journalslast month

    After court case loss, drug maker Akorn's CEO will step down

    After losing a court case in Delaware last week, the CEO of drug company Akorn Inc. will step down. Last week the Supreme Court of the State of Delaware upheld a lower court’s decision to allow Fresenius Kabi AG to terminate its April 2017 $4.3 billion merger deal with Lake Forest, Illinois-based Akorn. After the court loss was announced, Akorn said CEO Raj Rai will retire.

  • Is Akorn, Inc. (AKRX) A Good Stock To Buy?
    Insider Monkeylast month

    Is Akorn, Inc. (AKRX) A Good Stock To Buy?

    Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Reuters2 months ago

    Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

    Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE. The move comes after the Delaware Supreme Court on Friday upheld a decision by a lower court to allow Fresenius to walk away from its over $4 billion acquisition of Akorn that sent shares of the U.S generic drugmaker down more than 30 percent in regular trading. Akorn said that its Chief Executive Officer Raj Rai will retire but will remain in his post till a successor is named.

  • GlobeNewswire2 months ago

    Supreme Court of the State of Delaware Rules Against Akorn, New CEO Search Underway

    Akorn, Inc. (AKRX) today said it will move forward and rebuild shareholder value as an independent company following the disappointing decision from the Supreme Court of the State of Delaware upholding the lower court’s decision to allow Fresenius Kabi AG to terminate the April 2017 merger agreement. With the litigation process concluded, Akorn’s Board of Directors announced that it is engaged in a formal search for a new chief executive officer to lead the company into its next phase. Current CEO Raj Rai has decided to retire and will assist the board to ensure a smooth transition and remain in his role until the hiring date of the new chief executive.

  • Here's Why Akorn Pharmaceuticals Is Sinking Today
    Motley Fool2 months ago

    Here's Why Akorn Pharmaceuticals Is Sinking Today

    It looks as if the company's former suitor will get a chance to run from the altar.